20h
Celcuity Inc. Reports Release of First Quarter 2026 Financial Results and Provides Corporate Update
Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; detailed data for gedatolisib regimens will be presented ...
Phase 1b Registrational Clinical Study of SER-252 Underway in Advanced Parkinson's Disease; TFL data from the SAD study arm targeted for first half of 2027 - - Closed $21.2 million private placement ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results